Cargando…

A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile

Prostate-specific membrane antigen (PSMA) is a promising target for the treatment of advanced prostate cancer (PC) and various solid tumors. Although PSMA-targeted radiopharmaceutical therapy (RPT) has enabled significant imaging and prostate-specific antigen (PSA) responses, accumulating clinical d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boinapally, Srikanth, Ahn, Hye-Hyun, Cheng, Bei, Brummet, Mary, Nam, Hwanhee, Gabrielson, Kathleen L., Banerjee, Sangeeta R., Minn, Il, Pomper, Martin G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007718/ https://www.ncbi.nlm.nih.gov/pubmed/33782486 http://dx.doi.org/10.1038/s41598-021-86551-1

Ejemplares similares

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents
por: Chen, Ying, et al.
Publicado: (2022)

Preclinical Evaluation of a New Series of Albumin-Binding (177)Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
por: Boinapally, Srikanth, et al.
Publicado: (2023)

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
por: Minn, Il, et al.
Publicado: (2019)

Heterobivalent Agents Targeting PSMA and Integrin-α(v)β(3)
por: Shallal, Hassan M., et al.
Publicado: (2014)

A Unique Core–Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects
por: Cheng, Bei, et al.
Publicado: (2022)

A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA)
por: Banerjee, Sangeeta Ray, et al.
Publicado: (2011)

Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer
por: Shen, Colette J., et al.
Publicado: (2020)

Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating
por: Rowe, Steven P., et al.
Publicado: (2020)

Imaging of carbonic anhydrase IX with an (111)In-labeled dual-motif inhibitor
por: Yang, Xing, et al.
Publicado: (2015)

[(64)Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma
por: Minn, Il, et al.
Publicado: (2016)

Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers
por: Ahn, Hye-Hyun, et al.
Publicado: (2021)

Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors
por: Rogers, O. C., et al.
Publicado: (2021)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates
por: Xu, Bing, et al.
Publicado: (2018)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry
por: Zlitni, Aimen, et al.
Publicado: (2017)

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia
por: Werner, Rudolf A., et al.
Publicado: (2017)

A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (−) prostate cancer specific therapy
por: Wang, Yifan, et al.
Publicado: (2019)

A Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia
por: Datan, Emmanuel, et al.
Publicado: (2020)

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond
por: Hyväkkä, Anniina, et al.
Publicado: (2021)

Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer
por: Khatri, Wajahat, et al.
Publicado: (2021)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

Synthesis and Biochemical Evaluation of Baicalein Prodrugs
por: Son, Sang-Hyun, et al.
Publicado: (2021)

Evaluation of Antimalarial Activity and Toxicity of a New Primaquine Prodrug
por: Davanço, Marcelo Gomes, et al.
Publicado: (2014)

Novel prodrugs of decitabine with greater metabolic stability and less toxicity
por: Hattori, Naoko, et al.
Publicado: (2019)

Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer
por: Unger, Clara, et al.
Publicado: (2022)

(64)Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer
por: Banerjee, Sangeeta Ray, et al.
Publicado: (2014)

Tumor-Specific Imaging through Progression Elevated Gene-3 Promoter-Driven Gene Expression
por: Bhang, Hyo-eun C., et al.
Publicado: (2010)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization
por: Novakova, Zora, et al.
Publicado: (2020)

Tetrazine-mediated bioorthogonal prodrug–prodrug activation
por: Neumann, Kevin, et al.
Publicado: (2018)

Prodrugs and prodrug-activated systems in gene therapy
por: Sheikh, Semira, et al.
Publicado: (2021)

A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen
por: Liu, Guanshu, et al.
Publicado: (2017)

Comparison of Regularized Reconstruction and Ordered Subset Expectation Maximization Reconstruction in the Diagnostics of Prostate Cancer Using Digital Time-of-Flight (68)Ga-PSMA-11 PET/CT Imaging
por: Jonmarker, Olof, et al.
Publicado: (2021)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma
por: Vaughan, Hannah J., et al.
Publicado: (2022)

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
por: Platel, D, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_dp9jcjsv22og9katj951iqqpfe